Publicaties 1996 – 2002
70. Wolffenbuttel BHR, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996; 347: 513-515
71. The HOPE study investigators (incl Wolffenbuttel BHR). The HOPE (Heart Outcome Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12: 127-137
72. Treskes M, Wolffenbuttel BHR. Lange termijn schade van diabetes mellitus: de rol van irreversibele glyceringsproducten. Ned Tijdschr Geneeskd 1996; 140: 1299-1303
73. Bonnier JJRM, de Bruin TWA, Gevers Leuven JA, Hoogerbrugge N, Wolffenbuttel BHR. Hyperlipidemie anno 1996, de stand van zaken. Cardiologie 1996; 3 (suppl. 1): 5-10
74. Wolffenbuttel BHR. Monitoring and treatment of diabetes mellitus: some aspects for daily clinical practice. Klinicka Biochemie und Metabolismus (Tsjechie); 1996; 4(25): 160-163 (invited review)
75. Sels JPJE, Nauta JJP, Menheere PPCA, Wolffenbuttel BHR, Nieuwenhuijzen Kruseman AC. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers. Br J Clin Pharmacol 1996; 42: 503-506
76. Wolffenbuttel BHR, Graal MB. New treatment for patients with type 2 diabetes mellitus. Postgrad Med J 1996; 72: 657-662 (invited review)
77. Bruin TWA de, Wolffenbuttel BHR, Bonnier JJRM, Gevers Leuven JA, Hoogerbrugge N. Aanvullingen op het consensusbeleid bij diagnostiek en behandeling van hyperlipidemie in de praktijk. Ned Tijdschr Geneeskd 1996; 140: 2227-2230
78. Wolffenbuttel BHR. Can NIDDM be prevented by exercise? Int Diab Mon 1996; 8: 3-4
79. Gerstein HC, Bosch J, Pogue J, Taylor DW, Zinman B, Yusuf S, the HOPE study investigators (incl Wolffenbuttel BHR). Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes – the MICRO-HOPE study. Diabetes Care 1996; 19: 1225-1228.
80. Wolffenbuttel BHR, Sels JPJE, Rondas-Colbers GJWM, Menheere PPCA, Nieuwenhuijzen Kruseman AC. Comparison of different insulin regimens in patients with type 2 diabetes mellitus. Diabetes Care 1996; 19: 1326-1332
81. Leurs PB, Van Oerle R, Wolffenbuttel BHR, Hamulyak K. Increased Tissue Factor Pathway Inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Haemost 1997; 77: 472-476
82. Gonera RK, Oranje WA, Wolffenbuttel BHR. Shock of unknown origin – think of mastocytosis. Neth J Med 1997; 50: 165-168
83. De Haan CHA, Dielen FMH, Houben AJHM, De Leeuw PW, Huvers FC, De Mey JGR, Wolffenbuttel BHR, Schaper NC. Peripheral blood flow and noradrenaline responsiveness: the effect of physiological hyperinsulinemia. Cardiovasc Res 1997; 34: 192-198
84. Wolffenbuttel BHR, Denis-Thissen E. The use of insulin in the elderly. IDF Bulletin 1997; 42: 40-43
85. Lévy BI, Struijker Boudier HAJ, Wolffenbuttel BHR. Effets d’un traitement chronique par l’aminoguanidine sur les propriétés vasculaires dans un modèle de rat diabétique. Thérapie 1997; 52: 419-422
86. Wolffenbuttel BHR. Is van angiogenese-remmers (TNP-470, Batimastat, Marimastat) een preventieve of beschermende werking te verwachten bij diabetische retinopathie. Internisten Vademecum 1997; 22: 1-4
87. Wolffenbuttel BHR, Heine RJ. Kort- en snel werkende insuline analogen. Ned Tijdschr Geneeskd 1998; 142: 397-400
88. Wolffenbuttel BHR, Boulanger CM, Crijns FRL, Huijberts MSP, Poitevin P, Swennen GNM, Vasan S, Egan JJ, Cerami A, Lévy BI. Breakers of advanced glycation endproducts restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998; 4630 4634
89. Crijns FRL, Struijker Boudier HAJ, Wolffenbuttel BHR. Arterial reactivity in conscious diabetic rats. Influence of aminoguanidine treatment. Diabetes 1998; 47: 918 923
90. Wolffenbuttel BHR, Mahla G, Muller D, Pentrup A, Black DM. Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin in subjects with hypercholesterolemia. Neth J Med 1998; 52: 131-137
91. Wolffenbuttel BHR, Kitz K, Beuls EM. Beneficial gamma-knife radiosurgery in a patient with Nelson’s syndrome. Clin Neurol Neurosurg 1998; 100: 60-63
92. Wolffenbuttel BHR. Viewpoint on Repaglinide. Drugs & Aging 1998; 13: 181
93. Graal MB, Wolffenbuttel BHR. Long term complications of hyperparathyroidism. Neth J Med 1998; 53: 37-42
94. Oranje WA, Rondas-Colbers GJWM, Swennen GNM, Wolffenbuttel BHR. Lipid oxidation in type 2 diabetes: relationship with macrovascular disease? Neth J Med 1998; 53: 61-68
95. Wolffenbuttel BHR. Promoting exercise with a structured support programme. Int Diab Mon 1998; 10: 16
96. Sels JPJE, Verdonk HER, Wolffenbuttel BHR. Acarbose in type 1 diabetes. Diab Res Clin Pract 1998; 41: 139-145
97. Wolffenbuttel BHR. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). In: Disease Management Review. Auckland: Adis International, 1998: IV: 1-26. ISBN 0-86471-048-8
98. Wolffenbuttel BHR, Sels JPJE, Rondas-Colbers GJWM, Menheere PPCA. Prognostic factors for successful insulin therapy in subjects with type 2 diabetes. Neth J Med 1999; 54: 63-69
99. Wolffenbuttel BHR, Landgraf R. A one-year multicenter, randomized and double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes mellitus. Diabetes Care 1999; 22: 463-467
100. Engels W, Van Bilsen M, Wolffenbuttel BHR, Van der Vusse GJ, Glatz JFC. Cytochrome P450, peroxisome proliferation, and cytoplasmic fatty-acid-binding protein content in liver, heart and kidney of the diabetic rat. Mol Cell Biochem 1999; 192: 53-61
101. Oranje WA, Wolffenbuttel BHR. Lipid oxidation and atherosclerosis in type II diabetes mellitus (review). J Lab Clin Med 1999; 134: 19-32
102. Wolffenbuttel BHR. Viewpoint on Rosiglitazone. Drugs & Aging 1999; 57: 931-932
103. Blaak EE, Saris WH, Wolffenbuttel BHR. Substrate utilization and thermogenic responses to beta-adrenergic stimulation in obese subjects with NIDDM. Int J Obesity 1999; 23: 411-418
104. Huvers FC, De Leeuw PW, Houben AJHM, De Haan CHA, Hamulyak K, Schouten H, Wolffenbuttel BHR, Schaper NC. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic responses in type 1 diabetes mellitus under near-normoglycemic conditions. Diabetes 1999; 48: 1300-1307
105. Blaak EE, Kemerink GJ, Pakbiers MTW, Wolffenbuttel BHR, Heidendal GA, Saris WHM. Microdialysis assessment of local adipose tissue lipolysis during ß-adrenergic stimulation in upper-body-obese subjects with type II diabetes. Clinical Science 1999; 97: 421-428
106. Crijns FRL, Wolffenbuttel BHR, De Mey JG, Struijker Boudier HAJ. Mechanical properties of mesenteric arteries in diabetic rats: consequences of outward remodeling. Am J Physiol 1999; 276 (5 Pt 2): H1672-1677
107. Wolffenbuttel BHR, Heine RJ. Glykemische regulatie en behandeling van hypertensie bij personen met type 2 diabetes mellitus; de ‘United Kingdom prospective diabetes study’ naar diabetische complicaties. Ned Tijdschr Geneeskd 1999; 143: 1197-1201
108. Pols HAP, Felsenberg D, Hanley DA, for the Fosamax International Trial Study Group (incl. Wolffenbuttel BHR). Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bine mass: results of the FOSIT study. Osteoporos Int 1999; 9: 461-468
109. Van Maanen JMS, Albering HJ, Van Breda SGJ, Curfs DMJ, Ambergen AW, Wolffenbuttel BHR, Kleinjans JCS, Reeser HM. Nitrate in drinking water and risk of childhood diabetes in the Netherlands. Diabetes Care 1999; 22: 1750
110. Sels JP, Huijberts MSP, Wolffenbuttel BHR. Miglitol, a new alpha-glucosidase inhibitor. Expert Opinion Pharmacother 1999; 1: 149-156 (invited review)
111. Wolffenbuttel BHR. Repaglinide – a new compound for the treatment of patients with type 2 diabetes. Neth J Med 1999; 55: 229-234
112. Oranje WA, Rondas-Colbers GJWM, Swennen GNM, Jansen H, Wolffenbuttel BHR. Lack of effect on LDL oxidation and antioxidant status after improvement of metabolic control in type 2 diabetes. Diabetes Care 1999; 22: 2083-2084
113. Wolffenbuttel BHR. Drzewoski J. Prevention of complications in type 2 diabetes mellitus. Med Sci Mon 1999; 5: 1013-1019
114. Graal MB, Wolffenbuttel BHR. The use of sulphonylurea in the elderly. Drugs and Aging 1999; 15: 471-481 (invited review)
115. Schoon EJ, Wolffenbuttel BHR, Stockbrugger RW. Osteoporosis as a risk in inflammatory bowel disease. Drugs Today 1999; 35 (suppl. A): 17-32.
116. The HOPE Study Investigators (incl Wolffenbuttel BHR). Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
117. The HOPE Study Investigators (incl Wolffenbuttel BHR). Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 154-160.
118. Heart Outcomes Prevention Evaluation Study Investigators (incl Wolffenbuttel BHR). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000 Jan 22; 355(9200): 253-259.
119. Wolffenbuttel BHR, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetes patients. Diabetic Med 2000; 17: 40-47.
120. Sels JPJE, Wouters RMME, Lamers R, Wolffenbuttel BHR. Pitfall of the accessory spleen. Neth J Med 2000; 56: 153-158.
121. Wolffenbuttel BHR, Van Doorn LG, Mulder H, Sels JPJE, Engbers AMS, namens de HOPE-studie onderzoekers. Reductie van cardiovasculaire gebeurtenissen door behandeling met ramipril maar niet door behandeling met alfa-tocopherol bij patiënten met verhoogd risico; een gerandomiseerd, dubbelblind onderzoek. Ned Tijdschr Geneeskd 2000; 144: 990-995
122. Van Maanen JMS, Ambergen AW, Wolffenbuttel BHR, Reeser HM. Nitraat in drinkwater geen duidelijke risicofactor voor ontstaan van diabetes mellitus type 1 bij kinderen in Nederland. Ned Tijdschr Geneeskd 2000; 144: 1272-1276.
123. Van Maanen JMS, Albering HJ, de Kok TMCM, van Breda SGJ, Curfs DMJ, Vermeer ITM, Ambergen AW, Wolffenbuttel BHR, Kleinjans JCS, Reeser HM. Does the risk of childhood diabetes mellitus require revision of the guideline values for nitrate in drinking water? Environm Health Persp 2000; 108: 457-461.
124. Blaak EE, Wagenmakers AJ, Glatz JF, Wolffenbuttel BHR, Kemerink GJ, Langenberg CJ, Heidendal GA, Saris WH. Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. Am J Physiol Endocrinol Metab. 2000; 279(1): E146-154.
125. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BHR, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care. Int J Obes Relat Metab Disord. 2000; 24 (Suppl 3): S6-11.
126. Pieber ThR, I Eugene-Jolchine, E Derobert, and the European Study Group of HOE-901 in type 1 diabetes (incl. Wolffenbuttel BHR). Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000; 23: 157-162
127. Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BHR, Van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 583-588.
128. Kopff B, Mucha S, Wolffenbuttel BHR, Drzewoski J. Diabetic ketoacidosis in a patient with acromegaly. Curr Med Opin 2001; 7: 142-147
129. Blaak EE, Wolffenbuttel BHR, Saris WH, Pelsers MM, Wagenmakers AJ. Weight reduction and the impaired plasma-derived free fatty acid oxidation in type 2 diabetic subjects. J Clin Endocrinol Metab 2001; 86: 1638-1644.
130. Sels JP, Huijberts MS, Wolffenbuttel BHR. Miglitol, a new alpha-glucosidase inhibitor. Expert Opin Pharmacother. 1999; 1: 149-56.
131. Wolffenbuttel BHR, Sels JPJE, Huijberts MSP. Rosiglitazone – an insulin sensitiser and its place in the treatment of patients with type 2 diabetes. Expert Opinion Pharmacotherapy 2001; 2: 467-478 (invited review)
132. Wolffenbuttel BHR, Huijberts MSP. Gestoorde vetstofwisseling bij 3 patiënten met type 2 diabetes. Ned Tijdschr Geneeskd 2001; 145: 761-765.
133. Vrijhoef HJM, Diederiks JPM, Spreeuwenberg C, Wolffenbuttel BHR. Substitution model with central role for nurse specialist is justified for stable type 2 diabetic outpatients. J Adv Nursing 2001; 36: 546-556.
134. Vrijhoef HJM, Spreeuwenberg C, Eijkelberg IMJG, Wolffenbuttel BHR, Merode GG van. Adoption of disease management model for diabetes in regon of Maastricht. Br Med J 2001; 323: 983-985.
135. Oranje WA, Sels JPJE, Rondas-Colbers GJWM, Lemmens PJMR, Wolffenbuttel BHR. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta 2001; 311: 91-94.
136. de Clercq PA, Hasman A, Wolffenbuttel BHR. Design of a consumer health record for supporting the patient-centered management of chronic diseases. Medinfo 2001; 10 (Pt 2): 1445-1449.
137. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BHR, Zinman B. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885.
138. Heijckmann CA, Menheere PP, Sels JP, Beuls EA, Wolffenbuttel BHR. Clinical experience with Sandostatin LAR in patients with acromegaly. Neth J Med. 2001; 59: 286-91.
139. Eijkelberg IM, Spreeuwenberg C, Mur-Veeman IM, Wolffenbuttel BHR. From shared care to disease management: key-influencing factors. Int J Integr Care. 2001;1:e17.
140. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BHR, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002; 13: 221-7.
141. van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BHR, van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol. 2002; 13: 213-20.
142. Vrijhoef HJM, Diederiks JPM, Spreeuwenberg C, Wolffenbuttel BHR, Wilderen LJPG van. The nurse specialist as main care-provider for patients with type 2 diabetes in a primary care setting: effects on patient outcomes. Int J Nursing Studies 2002; 39: 441-451
143. Wolffenbuttel BHR. Postprandiale glucosepieken in de pathogenese van hart- en vaatziekten bij diabetes mellitus; consequenties voor de metabole regulatie. Ned Tijdschr Geneeskd 2002; 146: 654-658.
144. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BHR, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002; 25: 458-63.
145. Redekop WK, Koopmanschap MA, Rutten GE, Wolffenbuttel BHR, Stolk RP, Niessen LW. Resource consumption and costs in Dutch patients with type 2 diabetes mellitus. Results from 29 general practices. Diabet Med 2002; 19: 246-53.
146. Mentink CJ, Hendriks M, Levels AA, Wolffenbuttel BHR. Glucose-mediated cross-linking of collagen in rat tendon and skin. Clin Chim Acta 2002; 321: 69-76.
147. Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE, Wolffenbuttel BHR. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002; 25(8): 1340-5.
148. Heijckmann AC, Juttmann JR, Wolffenbuttel BHR. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med 2002; 60(8): 315-9.
Recente reacties